Immunotherapy after liver cancer surgery
Part of Cancer, Immune system & allergy clinical trials.
This trial tests whether giving an immunotherapy drug (anti-PD-1) after surgery can help prevent liver cancer from coming back. It is for people who have had their liver tumor completely removed and have good enough liver function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had surgery to completely remove your liver cancer.
- You have a confirmed diagnosis of hepatocellular carcinoma (the most common type of liver cancer).
- Your liver function is good enough (Child-Pugh grade A or B).
- You have not had any other cancer before or a recurrence of liver cancer.
- You have not had any prior treatment for liver cancer, like chemotherapy or targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This trial tests a new drug that combines two immunotherapy approaches (PD-1 and IL-2) given before surgery to treat hepatocellular carcinoma (liver cancer) that has come back 3 months to 2 years after your first surgery. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests how well immunotherapy drugs work for people with advanced liver cancer that cannot be treated with surgery. It focuses on patients whose liver is still working fairly well.
Hear when a new Adjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.